Immunovia publ AB (IMMNOV) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-0.84x
Immunovia publ AB (IMMNOV) has a Cash Flow-to-Debt Ratio of -0.84x as of June 2026, meaning its operating cash flow of Skr-20.57 Million could theoretically repay -1% of its total liabilities (Skr24.40 Million) in one year. See how financially flexible is Immunovia publ AB to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.84x
Operating CF / Total Liabilities
Operating Cash Flow
Skr-20.57 Million
SEK
Total Liabilities
Skr24.40 Million
SEK
Data as of
Jun 2026
Most recent filing
Immunovia publ AB Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Immunovia publ AB across 13 annual periods. For the full cash flow conversion analysis, see Immunovia publ AB cash conversion from operations.
Annual Cash Flow-to-Debt Ratio for Immunovia publ AB (2013–2025)
Year-by-year debt coverage analysis for Immunovia publ AB.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.34x | Skr-78.40 Million | Skr23.48 Million | ▲ +26.2% |
| 2024 | -4.52x | Skr-96.75 Million | Skr21.39 Million | ▲ +2.5% |
| 2023 | -4.64x | Skr-147.06 Million | Skr31.69 Million | ▼ -50.1% |
| 2022 | -3.09x | Skr-175.58 Million | Skr56.79 Million | ▼ -21.3% |
| 2021 | -2.55x | Skr-152.65 Million | Skr59.91 Million | ▼ -30.4% |
| 2020 | -1.95x | Skr-120.70 Million | Skr61.77 Million | ▼ -31.2% |
| 2019 | -1.49x | Skr-91.95 Million | Skr61.76 Million | ▲ +72.7% |
| 2018 | -5.45x | Skr-84.11 Million | Skr15.43 Million | ▼ -64.5% |
| 2017 | -3.31x | Skr-46.32 Million | Skr13.97 Million | ▼ -89.3% |
| 2016 | -1.75x | Skr-11.87 Million | Skr6.78 Million | ▼ -374.6% |
| 2015 | -0.37x | Skr-2.84 Million | Skr7.71 Million | ▲ +86.1% |
| 2014 | -2.65x | Skr-8.29 Million | Skr3.13 Million | ▼ -1514.7% |
| 2013 | -0.16x | Skr-414.31K | Skr2.53 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.